Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | G469S |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | BRAF G469S is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469S results in increased Erk phosphorylation (PMID: 27478040) and induces increased cell proliferation and cell viability compared to wild-type Braf in culture (PMID: 29533785). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF G469S BRAF mutant BRAF G469X BRAF G469S |
Transcript | NM_004333.6 |
gDNA | chr7:g.140781601_140781603delGGAinsAGC |
cDNA | c.1405_1407delGGAinsAGC |
Protein | p.G469S |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_005250045 | chr7:g.140781601_140781603delTCCinsGCT | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
NM_001378467.1 | chr7:g.140781610_140781612delGGAinsAGC | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140781601_140781603delTCCinsGCT | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
NM_001378470.1 | chr7:g.140777999_140778001delGGAinsAGC | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140781601_140781603delGGAinsAGC | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140781601_140781603delGGAinsAGC | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140781601_140781603delGGAinsAGC | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140781601_140781603delGGAinsAGC | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140781601_140781603delGGAinsAGC | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140781601_140781603delGGAinsAGC | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140781601_140781603delGGAinsAGC | c.1405_1407delGGAinsAGC | p.G469S | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF G469S | melanoma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in symptom improvement, reduced lymph node size, and decreased LDH levels in a patient with metastatic melanoma harboring BRAF G469S, with progression observed after three months (PMID: 31569065). | 31569065 |
BRAF G469S | melanoma | predicted - sensitive | Binimetinib + Encorafenib | Case Reports/Case Series | Actionable | In a Phase II trial (BEAVER), Mektovi (binimetinib) and Braftovi (encorafenib) combination therapy resulted in an unconfirmed partial response in a patient with melanoma harboring BRAF G469S (Annals of Oncology 32 (2021): S596; NCT03839342). | detail... |